RXDX — Prometheus Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge Cap
- $9.56bn
- $8.85bn
- $6.81m
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Solaredge Technologies
U.S. STOCKS ON THE MOVE-Uniti Group, Pfizer, Moleculin Biotech
Prometheus hits record high on positive data in inflammatory bowel disease trials
U.S. STOCKS ON THE MOVE-Prometheus, Pinterest, Roivant
Prometheus up on positive data in inflammatory bowel disease trials
Brief: Prometheus Biosciences Announces Positive Results For PRA023 In Artemis-UC Ph-2 And Apollo-CD Ph-2A Studies
U.S. RESEARCH ROUNDUP-Carvana, Centerspace, Lennox International
Brief: Prometheus Biosciences Receives FDA Clearance Of Ind Application For Its Second Precision Program, PRA052
U.S. RESEARCH ROUNDUP-Alliant Energy, Alnylam Pharmaceuticals, Constellation Energy
U.S. RESEARCH ROUNDUP-Envista Holdings, Shockwave Medical, Vivid Seats
U.S. STOCKS ON THE MOVE-Forza X1, GlobalFoundries, Avient
U.S. STOCKS ON THE MOVE-AirSculpt, Honest, Acer Therapeutics
CS raises PT for Prometheus on 'best-in-class' potential of IBD therapy
Brief: Prometheus Biosciences Reports Second Quarter 2022 Financial Results And Highlights Recent Corporate Progress
Brief: Prometheus Biosciences Plans To File IND For PRA052 In Q3
Brief: Prometheus Biosciences Completes Enrollment Of Artemis-UC Cohort 1 Phase 2 Study In Ulcerative Colitis
Brief: Prometheus Biosciences Provides Enrollment Update In Apollo-Cd And Artemis-Uc Global Phase 2 Studies
Brief: Prometheus Biosciences Reports Q1 2022 Results
Brief: Prometheus Biosciences Says Co Entered Into An Open Market Sale Agreement With Jefferies